Fulminant endocarditis and disseminated infection caused by carbapenem-resistant Acinetobacter baumannii in a renal-pancreas transplant recipient

Transplant Infectious Disease

Volumn 17, Issue 2, 2015, Pages 289-296

  Patel, G ^a   Perez, F ^b,c   Hujer, A M ^b,c   Rudin, S D ^b,c   Augustine, J J ^b,c,d   Jacobs, G H ^c   Jacobs, M R ^c   Bonomo, R A ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Louis Stokes Cleveland Veterans Administration   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Acinetobacter baumannii; Carbapenem resistance; Endocarditis; Simultaneous kidney pancreas transplantation

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CEFAZOLIN; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DORIPENEM; FLUCONAZOLE; GENTAMICIN; HYPERTENSIVE FACTOR; IMIPENEM; INSULIN; LEVOFLOXACIN; MEROPENEM; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLONE DERIVATIVE; SULTAMICILLIN; TACROLIMUS; THYMOCYTE ANTIBODY; TIGECYCLINE; TOBRAMYCIN; VALGANCICLOVIR; VANCOMYCIN; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE;

ABDOMINAL DISTENSION; ACIDOSIS; ACINETOBACTER; ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AMPLICON; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOPSY; BLOOD CULTURE; CARBAPENEM RESISTANT ACINETOBACTER BAUMANNII; CARDIOPULMONARY ARREST; CASE REPORT; DISEASE COURSE; ENDOCARDITIS; EXTUBATION; FAT NECROSIS; FEMALE; GRAFT RECIPIENT; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL HERNIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTENSIVE CARE; INTENSIVE CARE UNIT; ISCHEMIA; KIDNEY ALLOGRAFT; KIDNEY PANCREAS TRANSPLANTATION; LAPAROTOMY; LEUKOCYTOSIS; LEUKOPENIA; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; MYOCARDITIS; PATIENT HISTORY OF CHOLECYSTECTOMY; PERITONEAL DIALYSIS; PERITONEAL FLUID; PERITONITIS; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEPSIS; SUBSTITUTION THERAPY; TACHYCARDIA; URINE CULTURE; WEAKNESS; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL ENDOCARDITIS; DIABETES MELLITUS, TYPE 1; GENETICS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DIABETES MELLITUS, TYPE 1; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 84925344066     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12351     Document Type: Article

References (52)

1. Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014; 370 (13): 1198-1208.
2. Boucher HW, Talbot GH, Benjamin DK, et al. 10× '20 Progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013; 56 (12): 1685-1694.
3. van Duin D, van Delden C. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 31-41.
4. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34 (1): 1-14.
5. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 19th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
6. Pankey GA. Tigecycline. J Antimicrob Chemother 2005; 56 (3): 470-480.
7. Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50 (12): 4114-4123.
8. Perez F, Endimiani A, Ray AJ, et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010; 65 (8): 1807-1818.
9. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008; 358 (12): 1271-1281.
10. Pogue JM, Mann T, Barber KE, Kaye KS. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther 2013; 11 (4): 383-393.
11. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51 (10): 3471-3484.
12. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21 (3): 538-582.
13. Patel G, Bonomo R. "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 2013; 4: 48.
14. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Internat J Antimicrob Agents 2013; 41 (1): 11-19.
15. Kallen AJ, Hidron AI, Patel J, Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol 2010; 31 (5): 528-531.
16. Perez F, Hujer AM, Hulten EA, et al. Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in patients from a major military treatment facility. Am J Infect Control 2010; 38 (1): 63-65.
17. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003; 24 (4): 284-295.
18. Villar M, Cano ME, Gato E, et al. Epidemiologic and clinical impact of Acinetobacter baumannii colonization and infection: a reappraisal. Medicine 2014; 93 (5): 202-210.
19. Decker BK, Perez F, Hujer AM, et al. Longitudinal analysis of the temporal evolution of Acinetobacter baumannii strains in Ohio, USA, by using rapid automated typing methods. PLoS One 2012; 7 (4): e33443.
20. Thom KA, Maragakis LL, Richards K, et al. Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey. Infect Control Hosp Epidemiol 2012; 33 (9): 883-888.
21. Adams-Haduch JM, Onuoha EO, Bogdanovich T, et al. Molecular epidemiology of carbapenem-nonsusceptible Acinetobacter baumannii in the United States. J Clin Microbiol 2011; 49 (11): 3849-3854.
22. Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 2012; 7 (12): e52349.
23. Trottier V, Namias N, Pust DG, et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 2007; 8 (4): 437-443.
24. Nunley DR, Bauldoff GS, Mangino JE, Pope-Harman AL. Mortality associated with Acinetobacter baumannii infections experienced by lung transplant recipients. Lung 2010; 188 (5): 381-385.
25. de Gouvea EF, Martins IS, Halpern M, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC Infect Dis 2012; 12 : 351.
26. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15 (6): 980-982.
27. Martins N, Martins IS, de Freitas WV, et al. Severe infection in a lung transplant recipient caused by donor-transmitted carbapenem-resistant Acinetobacter baumannii. Transpl Infect Dis 2012; 14 (3): 316-320.
28. Sopirala MM, Pope-Harman A, Nunley DR, Moffatt-Bruce S, Ross P, Martin SI. Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients. J Heart Lung Transplant 2008; 27 (7): 804-807.
29. Shields RK, Kwak EJ, Potoski BA, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis 2011; 70 (2): 246-252.
30. Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transpl Infect Dis 2010; 12 (1): 87-93.
31. Shi SH, Kong HS, Xu J, et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis 2009; 11 (5): 405-412.
32. Kim YJ, Yoon JH, Kim SI, et al. High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc 2011; 43 (6): 2397-2399.
33. Clemente WT, Sanches MD, Coutinho RL, et al. Multidrug-resistant Acinetobacter baumannii causing necrotizing fasciitis in a pancreas-kidney transplant recipient: a case report. Transplantation 2012; 94 (6): e37-e38.
34. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
35. Wright MS, Haft DH, Harkins DM, et al. New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio 2014; 5 (1): e00963-e00913.
36. Bruhn KW, Pantapalangkoor P, Nielsen T, et al. Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia. J Infect Dis 2014; Nov 5. [Epub ahead of print].
37. Lumbreras C, Sanz F, González A, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis 2001; 33 (5): 722-726.
38. Sifri CD, Ison MG. Highly resistant bacteria and donor-derived infections: treading in uncharted territory. Transpl Infect Dis 2012; 14 (3): 223-228.
39. Ison MG, Grossi P. Donor-derived infections in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 22-30.
40. Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014; 20 (5): 416-423.
41. Ecker DJ, Massire C, Blyn LB, et al. Molecular genotyping of microbes by multilocus PCR and mass spectrometry: a new tool for hospital infection control and public health surveillance. Methods Molec Biol 2009; 551: 71-87.
42. Lin YC, Sheng WH, Chang SC, et al. Application of a microsphere-based array for rapid identification of Acinetobacter spp. with distinct antimicrobial susceptibilities. J Clin Microbiol 2008; 46 (2): 612-617.
43. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55 (7): 3284-3294.
44. Rao GG, Ly NS, Haas CE, et al. New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother 2014; 58 (3): 1381-1388.
45. Dixit D, Madduri RP, Sharma R. The role of tigecycline in the treatment of infections in light of the new black box warning. Expert Rev Anti Infect Ther 2014; 12 (4): 397-400.
46. Adnan S, Paterson DL, Lipman J, Roberts JA. Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. Internat J Antimicrob Agents 2013; 42 (5): 384-389.
47. Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013; 57 (10): 5104-5111.
48. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57 (3): 349-358.
49. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014; 58 (9): 5598-5601.
50. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014; 74 (12): 1315-1333.
51. Gradon JD, Chapnick EK, Lutwick LI. Infective endocarditis of a native valve due to Acinetobacter: case report and review. Clin Infect Dis 1992; 14 (5): 1145-1148.
52. Perez F, Bonomo RA. Vaccines for Acinetobacter baumannii: thinking "out of the box". Vaccine 2014; 32 (22): 2537-2539.